Browse CHRNB2

Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein.
Domain PF02931 Neurotransmitter-gated ion-channel ligand binding domain
PF02932 Neurotransmitter-gated ion-channel transmembrane region
Function

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.

> Gene Ontology
 
Biological Process GO:0001508 action potential
GO:0001661 conditioned taste aversion
GO:0001666 response to hypoxia
GO:0001963 synaptic transmission, dopaminergic
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0003012 muscle system process
GO:0003014 renal system process
GO:0006584 catecholamine metabolic process
GO:0006816 calcium ion transport
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0007270 neuron-neuron synaptic transmission
GO:0007271 synaptic transmission, cholinergic
GO:0007274 neuromuscular synaptic transmission
GO:0007409 axonogenesis
GO:0007416 synapse assembly
GO:0007588 excretion
GO:0007601 visual perception
GO:0007605 sensory perception of sound
GO:0007611 learning or memory
GO:0007612 learning
GO:0007613 memory
GO:0007622 rhythmic behavior
GO:0007623 circadian rhythm
GO:0007626 locomotory behavior
GO:0007631 feeding behavior
GO:0007632 visual behavior
GO:0008306 associative learning
GO:0008542 visual learning
GO:0009308 amine metabolic process
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009712 catechol-containing compound metabolic process
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0014046 dopamine secretion
GO:0014059 regulation of dopamine secretion
GO:0015837 amine transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015872 dopamine transport
GO:0016358 dendrite development
GO:0018958 phenol-containing compound metabolic process
GO:0019233 sensory perception of pain
GO:0021536 diencephalon development
GO:0021545 cranial nerve development
GO:0021554 optic nerve development
GO:0021562 vestibulocochlear nerve development
GO:0021602 cranial nerve morphogenesis
GO:0021631 optic nerve morphogenesis
GO:0021675 nerve development
GO:0021771 lateral geniculate nucleus development
GO:0021794 thalamus development
GO:0021952 central nervous system projection neuron axonogenesis
GO:0021953 central nervous system neuron differentiation
GO:0021954 central nervous system neuron development
GO:0021955 central nervous system neuron axonogenesis
GO:0022410 circadian sleep/wake cycle process
GO:0022604 regulation of cell morphogenesis
GO:0030431 sleep
GO:0030534 adult behavior
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0030900 forebrain development
GO:0032225 regulation of synaptic transmission, dopaminergic
GO:0032226 positive regulation of synaptic transmission, dopaminergic
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033238 regulation of cellular amine metabolic process
GO:0033603 positive regulation of dopamine secretion
GO:0033605 positive regulation of catecholamine secretion
GO:0035094 response to nicotine
GO:0035095 behavioral response to nicotine
GO:0035176 social behavior
GO:0036293 response to decreased oxygen levels
GO:0042053 regulation of dopamine metabolic process
GO:0042069 regulation of catecholamine metabolic process
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0042220 response to cocaine
GO:0042320 regulation of circadian sleep/wake cycle, REM sleep
GO:0042391 regulation of membrane potential
GO:0042417 dopamine metabolic process
GO:0042745 circadian sleep/wake cycle
GO:0042747 circadian sleep/wake cycle, REM sleep
GO:0042748 circadian sleep/wake cycle, non-REM sleep
GO:0042749 regulation of circadian sleep/wake cycle
GO:0042752 regulation of circadian rhythm
GO:0043279 response to alkaloid
GO:0044106 cellular amine metabolic process
GO:0044708 single-organism behavior
GO:0045187 regulation of circadian sleep/wake cycle, sleep
GO:0045188 regulation of circadian sleep/wake cycle, non-REM sleep
GO:0045471 response to ethanol
GO:0045759 negative regulation of action potential
GO:0046651 lymphocyte proliferation
GO:0048511 rhythmic process
GO:0048512 circadian behavior
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0048857 neural nucleus development
GO:0050432 catecholamine secretion
GO:0050433 regulation of catecholamine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050773 regulation of dendrite development
GO:0050795 regulation of behavior
GO:0050802 circadian sleep/wake cycle, sleep
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0050890 cognition
GO:0050953 sensory perception of light stimulus
GO:0050954 sensory perception of mechanical stimulus
GO:0051047 positive regulation of secretion
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051259 protein oligomerization
GO:0051291 protein heterooligomerization
GO:0051703 intraspecies interaction between organisms
GO:0051705 multi-organism behavior
GO:0051899 membrane depolarization
GO:0051937 catecholamine transport
GO:0051952 regulation of amine transport
GO:0051954 positive regulation of amine transport
GO:0051963 regulation of synapse assembly
GO:0060073 micturition
GO:0060084 synaptic transmission involved in micturition
GO:0061564 axon development
GO:0070482 response to oxygen levels
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0072511 divalent inorganic cation transport
GO:0097305 response to alcohol
GO:0098900 regulation of action potential
GO:1901615 organic hydroxy compound metabolic process
GO:1903532 positive regulation of secretion by cell
Molecular Function GO:0004889 acetylcholine-activated cation-selective channel activity
GO:0005216 ion channel activity
GO:0005230 extracellular ligand-gated ion channel activity
GO:0005231 excitatory extracellular ligand-gated ion channel activity
GO:0005261 cation channel activity
GO:0008144 drug binding
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0015464 acetylcholine receptor activity
GO:0022803 passive transmembrane transporter activity
GO:0022834 ligand-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0030594 neurotransmitter receptor activity
GO:0042165 neurotransmitter binding
GO:0042166 acetylcholine binding
GO:0046982 protein heterodimerization activity
GO:0070405 ammonium ion binding
Cellular Component GO:0005892 acetylcholine-gated channel complex
GO:0009897 external side of plasma membrane
GO:0034702 ion channel complex
GO:0043235 receptor complex
GO:0045211 postsynaptic membrane
GO:0097060 synaptic membrane
GO:0098552 side of membrane
GO:0098794 postsynapse
GO:0098802 plasma membrane receptor complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04725 Cholinergic synapse
Reactome R-HSA-181431: Acetylcholine Binding And Downstream Events
R-HSA-629602: Activation of Nicotinic Acetylcholine Receptors
R-HSA-629597: Highly calcium permeable nicotinic acetylcholine receptors
R-HSA-629594: Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
R-HSA-629587: Highly sodium permeable acetylcholine nicotinic receptors
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-622327: Postsynaptic nicotinic acetylcholine receptors
R-HSA-622323: Presynaptic nicotinic acetylcholine receptors
R-HSA-112315: Transmission across Chemical Synapses
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CHRNB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CHRNB2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CHRNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5860.275
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.3830.111
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3550.601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5390.661
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1180.931
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4050.655
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6610.596
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5020.715
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3580.504
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2510.735
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7140.00829
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CHRNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHRNB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHRNB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHRNB2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHRNB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CHRNB2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CHRNB2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCHRNB2
Namecholinergic receptor, nicotinic, beta 2 (neuronal)
Aliases acetylcholine receptor, nicotinic, beta 2 (neuronal); cholinergic receptor, nicotinic, beta polypeptide 2 (n ......
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CHRNB2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CHRNB2.
ID Name Drug Type Targets #Targets
DB00184NicotineSmall MoleculeCHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHR ......13
DB00514DextromethorphanSmall MoleculeCHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A ......21
DB00564CarbamazepineSmall MoleculeCHRNA4, CHRNB2, NR1I2, SCN5A4
DB00572AtropineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA4, CHRNB2, GLRA18
DB00657MecamylamineSmall MoleculeCHRNA2, CHRNA4, CHRNA7, CHRNB24
DB00674GalantamineSmall MoleculeACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA ......18
DB00747ScopolamineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA4, CHRNB2, SI8
DB00898EthanolSmall MoleculeCACNA1C, CACNA1D, CACNA1S, CACNB1, CACNG1, CACNG2, CHRNA10, CHRNA2 ......52
DB00981PhysostigmineSmall MoleculeACHE, CHRNA4, CHRNB23
DB01245DecamethoniumSmall MoleculeACHE, CHRNA2, CHRNA4, CHRNB24
DB01273VareniclineSmall MoleculeCHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB25
DB05458PozaniclineSmall MoleculeCHRNA4, CHRNB22
DB05740RPI-78MSmall MoleculeCHRNA10, CHRNA2, CHRNA4, CHRNA7, CHRNA9, CHRNB26
DB05855RivaniclineSmall MoleculeCHRNB2, CXCL82
DB07720EpibatidineSmall MoleculeCHRFAM7A, CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB47
DB09028CytisineSmall MoleculeCHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB25